Jonathan is an Associate Director in our London corporate team.
Jonathan works on a broad range of corporate transactions and has particular experience of advising on domestic and cross-border mergers and acquisitions, venture capital investments, joint ventures and general corporate matters in the Life Sciences and Healthcare sector.
Jonathan qualified as a New Zealand barrister and solicitor in December 2011. He joined Osborne Clarke in August 2016 from Linklaters’ London corporate team. Prior to arriving in the UK he worked at Minter Ellison Rudd Watts, one of New Zealand’s leading full-service law firms, where he spent five years advising on a diverse range of matters in the firm’s corporate and commercial team.
Advised the shareholders of Argint International on the disposal of the group to Precision Medicine Group.
AMI Entertainment and Harbour Group
Advised AMI Entertainment and Harbour Group in relation to the acquisition of NSM Music Group.
Takeda Pharmaceutical Company
Advised Takeda on its investment in, and option to acquire, Adaptate Biotherapeutics.
Advised RHYTHM AI, a UK company focused on the treatment of Atrial Fibrillation (AF), on the closure of a £2.15m seed financing round. Read more >
Advised MedAnnex on the closure of its £11m Series B financing round led by Morningside Ventures. Read more >
Advised Thirty Holdings on the closure of a £25m financing round led by Morningside Ventures and associated corporate restructuring.
Advised TTS Pharma on the closure of a £10.3m financing round.
Secure Code Warrior
Advised Secure Code Warrior on the closure of its $47.6M Series B round led by Goldman Sachs. Read more >
Advised the shareholders of Gram Games on the $250 million sale to Zynga. Read more >